Celldex Therapeutics, Inc. (NASDAQ:CLDX) Shares Bought by Arizona State Retirement System

Arizona State Retirement System increased its stake in Celldex Therapeutics, Inc. (NASDAQ:CLDX) by 2.0% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 16,231 shares of the biopharmaceutical company’s stock after acquiring an additional 325 shares during the period. Arizona State Retirement System’s holdings in Celldex Therapeutics were worth $601,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD boosted its holdings in shares of Celldex Therapeutics by 631.1% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,087,208 shares of the biopharmaceutical company’s stock valued at $129,571,000 after purchasing an additional 2,664,915 shares during the last quarter. Eventide Asset Management LLC boosted its holdings in Celldex Therapeutics by 126.9% in the fourth quarter. Eventide Asset Management LLC now owns 3,630,013 shares of the biopharmaceutical company’s stock valued at $143,966,000 after acquiring an additional 2,030,013 shares during the last quarter. Point72 Asset Management L.P. grew its position in Celldex Therapeutics by 105.3% during the fourth quarter. Point72 Asset Management L.P. now owns 2,756,122 shares of the biopharmaceutical company’s stock valued at $109,308,000 after acquiring an additional 1,413,722 shares during the period. Wellington Management Group LLP grew its position in Celldex Therapeutics by 19.2% during the fourth quarter. Wellington Management Group LLP now owns 6,476,561 shares of the biopharmaceutical company’s stock valued at $256,860,000 after acquiring an additional 1,044,728 shares during the period. Finally, Jennison Associates LLC increased its stake in Celldex Therapeutics by 3,327.0% during the first quarter. Jennison Associates LLC now owns 688,080 shares of the biopharmaceutical company’s stock worth $28,879,000 after acquiring an additional 668,002 shares during the last quarter.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on CLDX. Cantor Fitzgerald reiterated an “overweight” rating and set a $67.00 target price on shares of Celldex Therapeutics in a report on Monday, September 9th. HC Wainwright reissued a “buy” rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research report on Monday, August 12th. Stifel Nicolaus assumed coverage on shares of Celldex Therapeutics in a report on Tuesday, June 18th. They set a “buy” rating and a $58.00 target price on the stock. Wells Fargo & Company increased their price target on Celldex Therapeutics from $35.00 to $37.00 and gave the company an “equal weight” rating in a report on Monday, August 12th. Finally, Wolfe Research started coverage on Celldex Therapeutics in a research note on Tuesday, June 11th. They set an “outperform” rating and a $51.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $63.83.

Celldex Therapeutics Price Performance

NASDAQ:CLDX opened at $44.16 on Monday. The firm has a 50-day moving average of $38.14 and a two-hundred day moving average of $38.87. The stock has a market cap of $2.93 billion, a P/E ratio of -15.49 and a beta of 1.56. Celldex Therapeutics, Inc. has a 1-year low of $22.11 and a 1-year high of $53.18.

Celldex Therapeutics (NASDAQ:CLDX) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.54) EPS for the quarter, beating analysts’ consensus estimates of ($0.59) by $0.05. Celldex Therapeutics had a negative return on equity of 23.66% and a negative net margin of 1,809.18%. The firm had revenue of $2.50 million during the quarter, compared to the consensus estimate of $1.13 million. As a group, equities analysts expect that Celldex Therapeutics, Inc. will post -2.5 earnings per share for the current year.

Celldex Therapeutics Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.